
Annual report 2025
added 02-17-2026
Boston Scientific Corporation Net Income 2011-2026 | BSX
Net profit is a financial indicator that reflects the remaining amount of money after deducting all expenses and taxes from the company’s total income over a certain period of time. It is one of the key indicators of a company’s financial stability and success.
Net profit is the portion of total profit remaining after taxes and depreciation have been deducted.[1]
It is the result of a company’s operations and reflects its efficiency in managing resources, controlling expenses, and generating income. It includes all operating revenues and expenses, such as sales of goods or services, production costs, administrative expenses, taxes, and other financial metrics.
The calculation of net profit includes the deduction of all necessary expenses such as employee salaries, rent, utilities, taxes, and other mandatory payments. After all these expenses are deducted from the total income, the remaining amount is considered the company’s net profit.
Net profit is an important indicator of a company’s financial health, as it reflects its ability to generate earnings and manage its finances. High net profit indicates business success, competitiveness, and efficiency in resource utilization. It also allows a company to invest in its development, pay dividends to shareholders, or create reserve funds for unforeseen situations.
It serves as a basis for calculating other financial indicators, such as return on sales, return on assets, or return on equity. It is also used to assess the performance of management and make decisions regarding the future development of the company.
However, it should be noted that net profit can be affected by various factors, such as economic conditions, changes in legislation, market competition, and other external influences. Therefore, companies must be prepared for possible changes and take measures to ensure the stability of their financial results.
Annual Net Income Boston Scientific Corporation
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2.89 B | 1.85 B | 1.59 B | 698 M | 1.04 B | -82 M | 4.7 B | 1.67 B | 104 M | 347 M | -239 M | -119 M | -121 M | -4.07 B | 441 M |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 4.7 B | -4.07 B | 714 M |
Quarterly Net Income Boston Scientific Corporation
| 2025-Q3 | 2025-Q2 | 2025-Q1 | 2024-Q3 | 2024-Q2 | 2024-Q1 | 2023-Q3 | 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 755 M | 795 M | 672 M | 468 M | 322 M | 493 M | 504 M | 270 M | 314 M | - | 188 M | 260 M | 110 M | - | 419 M | 186 M | 341 M | - | -155 M | -147 M | 11 M | - | 126 M | 154 M | 424 M | - | 432 M | 555 M | 298 M | - | 283 M | 146 M | 290 M | - | 228 M | -207 M | 202 M | - | -198 M | 102 M | -1 M | - | 43 M | 4 M | 133 M | - | -5 M | 130 M | -354 M | - | -664 M | -3.58 B | 113 M | - | 142 M | 146 M | 46 M |
All numbers in USD currency
Indicator range from quarterly reporting
| Maximum | Minimum | Average |
|---|---|---|
| 795 M | -3.58 B | 107 M |
References
- Bhamornsiri, S., & Wiggins, C. (2001). Comprehensive income disclosures. The CPA Journal, 71(10), 54.
Net Income of other stocks in the Medical devices industry
| Issuer | Net Income | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
|
Aethlon Medical
AEMD
|
-13.4 M | $ 2.22 | 5.21 % | $ 3.47 M | ||
|
Acutus Medical
AFIB
|
-81.7 M | - | -26.83 % | $ 2.62 M | ||
|
Allied Healthcare Products
AHPI
|
-1.94 M | - | 3.58 % | $ 2.21 M | ||
|
AdaptHealth Corp.
AHCO
|
-70.8 M | $ 10.45 | 0.29 % | $ 1.41 B | ||
|
GenMark Diagnostics, Inc.
GNMK
|
-18.6 M | - | - | $ 1.77 B | ||
|
Cognyte Software Ltd.
CGNT
|
-12.1 M | $ 8.36 | -0.24 % | $ 600 M | ||
|
Alphatec Holdings
ATEC
|
-143 M | $ 13.05 | 3.57 % | $ 1.96 B | ||
|
Obalon Therapeutics, Inc.
OBLN
|
-12.3 M | - | -5.86 % | $ 30.6 M | ||
|
Avinger
AVGR
|
-18.3 M | - | -20.74 % | $ 369 K | ||
|
Aziyo Biologics
AZYO
|
53.4 M | - | 1.37 % | $ 20.5 M | ||
|
Butterfly Network
BFLY
|
-72.5 M | $ 4.27 | 9.21 % | $ 904 M | ||
|
BIOLASE
BIOL
|
-20.6 M | - | -13.19 % | $ 166 K | ||
|
Conformis
CFMS
|
-50.5 M | - | - | $ 16.4 M | ||
|
EDAP TMS S.A.
EDAP
|
-19 M | $ 4.06 | 2.53 % | $ 151 M | ||
|
Apollo Endosurgery
APEN
|
-39.8 M | - | - | $ 475 M | ||
|
CONMED Corporation
CNMD
|
47.1 M | $ 37.34 | -0.16 % | $ 1.16 B | ||
|
CryoLife, Inc.
CRY
|
-16.7 M | - | -4.14 % | $ 702 M | ||
|
Cytosorbents Corporation
CTSO
|
-20.7 M | $ 0.68 | 4.61 % | $ 37 M | ||
|
Cutera
CUTR
|
-57.2 M | - | -10.19 % | $ 1.99 M | ||
|
ClearPoint Neuro
CLPT
|
-25.5 M | $ 11.16 | 1.18 % | $ 302 M | ||
|
Dynatronics Corporation
DYNT
|
-10.9 M | - | 14.99 % | $ 929 K | ||
|
Axonics Modulation Technologies
AXNX
|
-59.7 M | - | - | $ 3.31 B | ||
|
Soliton, Inc.
SOLY
|
-14.5 M | - | -1.42 % | $ 435 M | ||
|
Hancock Jaffe Laboratories, Inc.
HJLI
|
-9.14 K | - | -1.98 % | $ 98.3 M | ||
|
Establishment Labs Holdings
ESTA
|
-51.1 M | $ 65.01 | 2.41 % | $ 1.93 B | ||
|
Itamar Medical Ltd.
ITMR
|
-10.9 M | - | 0.03 % | $ 1.58 B | ||
|
Misonix, Inc.
MSON
|
-17.4 M | - | - | $ 462 M | ||
|
Neovasc
NVCN
|
-24.9 M | - | - | $ 111 M | ||
|
FONAR Corporation
FONR
|
12.4 M | $ 18.45 | 0.16 % | $ 121 M | ||
|
InMode Ltd.
INMD
|
93.8 M | $ 13.65 | 1.64 % | $ 882 M | ||
|
Intersect ENT, Inc.
XENT
|
-72.3 M | - | - | $ 955 M | ||
|
GBS
GBS
|
-10.6 M | - | -0.57 % | $ 7.12 M | ||
|
Abbott Laboratories
ABT
|
6.52 B | $ 110.71 | 0.69 % | $ 193 B | ||
|
Delcath Systems
DCTH
|
2.7 M | $ 9.74 | -0.71 % | $ 349 M | ||
|
Nano-X Imaging Ltd.
NNOX
|
-53.5 M | $ 2.6 | 0.39 % | $ 153 M | ||
|
Bio-Rad Laboratories
BIO
|
-716 M | $ 269.48 | 3.15 % | $ 7.6 B | ||
|
Helius Medical Technologies
HSDT
|
-8.85 M | $ 2.17 | -0.91 % | $ 1.32 M | ||
|
AxoGen
AXGN
|
-15.7 M | $ 32.75 | -0.27 % | $ 1.51 B | ||
|
Align Technology
ALGN
|
421 M | $ 176.12 | 3.94 % | $ 13.2 B | ||
|
Integra LifeSciences Holdings Corporation
IART
|
-6.94 M | $ 9.1 | 1.0 % | $ 701 M | ||
|
Bruker Corporation
BRKR
|
113 M | $ 33.74 | 2.99 % | $ 5.03 K | ||
|
BioSig Technologies
BSGM
|
-10.3 M | - | 37.08 % | $ 85.7 M | ||
|
Apyx Medical Corporation
APYX
|
-11.2 M | $ 3.74 | 1.91 % | $ 154 M | ||
|
Second Sight Medical Products
EYES
|
-23.5 M | - | -0.97 % | $ 54.4 M | ||
|
Accuray Incorporated
ARAY
|
-1.59 M | $ 0.39 | -6.07 % | $ 40.1 M | ||
|
IRIDEX Corporation
IRIX
|
-9.57 M | $ 1.33 | - | $ 21.5 M | ||
|
IRadimed Corporation
IRMD
|
22.5 M | $ 102.8 | 1.09 % | $ 1.31 B |